Functionally, treatment with TNBC-derived plasma small-EVs not only downregulated expression of epithelial marker CDH1, and upregulated expression of the mesenchymal markers ZEB2 and FN1 in low-invasive MCF-7 breast cancer cells, but also elevated expression of inflammatory and matrix-remodeling mediators (Il-6, Tnf-α, and Mmp-9) in BNL CL.2 normal liver cells. Here, MMP9 is linked to breast cancer.